What Pharma Already Knows About AI Act Compliance

I spent years managing compliance programs in pharma. GxP, validation protocols, change control, deviation management, qualified persons, audit trails. I learned one rule that never changes: if it isn't documented, it didn't happen. This principle governs everything from raw material sourcing to drug storage to clinical trial oversight.

Then I started working with organizations on EU AI Act compliance. And I immediately recognized the pattern. The Act doesn't require anything pharma doesn't already do. It's just applying pharma's governance model to AI systems.

This is strategically important. Organizations staffed with pharma veterans—compliance officers, quality managers, project leads—should understand that they already know how to run AI governance. They don't need to learn a new discipline. They need to translate existing skills.

Documentation Is Not Optional

In pharma, documentation is the evidence. If a batch of medication was manufactured properly, you know because the batch record documents every step. If a process change was evaluated for impact, you know because the risk assessment is documented. If a supplier was qualified, you know because the qualification report exists. The principle is simple and unforgiving: if something important happened, it must be documented, or it is assumed not to have happened.

Article 11 of the EU AI Act requires extensive technical documentation of high-risk AI systems. What does the system do? What data was it trained on? How was it tested? What risks were identified? How are those risks mitigated? Article 12 requires automatic logging of system decisions. These requirements mirror pharma's batch records and deviation logs. They're the audit trail that proves the system operated as intended.

Organizations with pharma background understand this instinctively. Documentation is not bureaucratic overhead. It's evidence. It's the proof that governance happened. Pharma teams will naturally build documentation into system design because they've learned that doing it later is infinitely more expensive.

Validation Is Continuous, Not One-Time

Pharma does not validate a process once and declare it safe forever. Validation is continuous. You establish the process design qualification, then you prove it works through process performance qualification, and then you monitor performance continuously through the lifecycle. If performance changes, you investigate. If parameters drift, you escalate.

Article 9 of the EU AI Act requires continuous risk management. The system must be monitored for performance degradation, bias emergence, and shifting outcomes. When risk changes, the organization must respond. This is not a one-time audit. It's ongoing surveillance of system behavior against defined thresholds.

Pharma people understand this. They know that monitoring data from day 100 of operation tells you different things than monitoring data from day 1. They know that assumptions that held initially may not hold over time. They know that governance is not an event, it's a process.

Change Control Is Not Optional

In pharma, you cannot modify a manufacturing process without documenting why, analyzing impact, getting approval, and maintaining records. A change to raw material suppliers, production equipment, staffing levels, or environmental controls all trigger change control. You assess risk, implement controls, verify effectiveness.

Article 6 of the EU AI Act applies similar logic to AI systems. Substantial modifications to a system trigger re-assessment. If you update the training data, change the model architecture, adjust decision thresholds, or expand the use case, this is a substantial modification. The organization must reassess risk and ensure continued compliance. The rationale for this decision must be documented.

Pharma teams already know that changes seem small until they aren't. A single new supplier sometimes introduces unexpected variability. A tweak to process parameters sometimes creates cascade effects. Pharma governance around change control exists because organizations learned that documentation and impact assessment prevent disasters.

Human Oversight Is Embedded, Not Rubber-Stamped

Pharma uses qualified persons—individuals with specific technical knowledge and authority—to oversee critical decisions. A qualified person does not review documents after the fact. They have embedded decision authority. They can halt a process if they determine something is unsafe. Their oversight is active, not passive.

Article 14 of the EU AI Act requires human oversight for high-risk systems. This does not mean humans reviewing outputs after the system acts. It means humans with sufficient training and authority to understand the system, monitor its behavior, and intervene when something seems wrong. This is the qualified person model applied to AI.

Pharma teams understand that human oversight requires people with real authority, not committee signatures. Oversight requires expertise, not just hierarchy. And oversight requires the ability to stop a process, not just to observe it.

The Strategic Implication

Organizations that hire pharma compliance professionals to lead AI governance have a significant advantage. These people speak the language of documented evidence, continuous monitoring, and embedded oversight. They understand that governance enables quality, not restricts it. They know that shortcuts in documentation create risks later. They understand the difference between compliance theater and actual controls.

Organizations starting AI governance from scratch, without pharma expertise, must learn these principles through trial and error. Organizations with pharma veterans can shortcut that learning. The principles are already known. The discipline is already internalized. The frameworks already exist. They just need to be translated from pharmaceutical processes to AI systems.

If you're building an AI governance program, hire someone who's managed compliance in pharma. They don't need to learn governance. They need to apply what they already know to a new domain. That acceleration is worth far more than the cost of the hire.